Product Center
Received National-Level Recognition!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-01
- Views:
(Summary description)Recommended by provincial adverse drug reaction monitoring institutions and evaluated by the National Center for Adverse Drug Reaction Monitoring, Ab&B Bio-Tech Co., Ltd. JS demonstrated outstanding performance in fulfilling its primary responsibilities for adverse drug reaction monitoring in 2023 and was commended by the National Center.
Received National-Level Recognition!
(Summary description)Recommended by provincial adverse drug reaction monitoring institutions and evaluated by the National Center for Adverse Drug Reaction Monitoring, Ab&B Bio-Tech Co., Ltd. JS demonstrated outstanding performance in fulfilling its primary responsibilities for adverse drug reaction monitoring in 2023 and was commended by the National Center.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-01 16:18
- Views:
Recommended by provincial adverse drug reaction monitoring institutions and evaluated by the National Center for Adverse Drug Reaction Monitoring, Ab&B Bio-Tech Co., Ltd. JS demonstrated outstanding performance in fulfilling its primary responsibilities for adverse drug reaction monitoring in 2023 and was commended by the National Center.
This recognition reflects the affirmation of Ab&B Bio-Tech Co., Ltd. JS's preliminary work by monitoring institutions at all levels. The company will cherish this honor, continue to implement the "four strictest" requirements and General Secretary Xi Jinping's directives on drug safety, and enhance pharmacovigilance capabilities to safeguard public health.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
